Financial Data and Key Metrics Changes - Revenue for Q3 2025 was reported at $20.7 million, reflecting a 9% growth year-over-year, driven by stronger adoption and new accounts [4][14] - Gross margin remained stable at 68% for both Q3 2025 and Q3 2024, with gross profit increasing to $14 million from $12.9 million [14] - Net loss decreased to $8.6 million in Q3 2025 from $10.4 million in the prior year [16] Business Line Data and Key Metrics Changes - Revenue from OviTex grew by 6%, while OviTex PRS revenue increased by 12% compared to the prior year [14] - OviTex unit sales grew by 22% in Q3, while PRS unit sales saw a 3% increase [14] Market Data and Key Metrics Changes - International sales grew by 9%, with notable traction in the U.K. and early progress from the OviTex IHR launch in Europe [4] - The company expanded its market presence in the U.S. by adding 835 hospitals to its portfolio [9] Company Strategy and Development Direction - The company is focused on expanding its commercial footprint, improving operational discipline, and strengthening its patient-centric culture [4] - Investments in the sales organization are expected to enhance commercial performance moving forward [5] - The company aims to become a market leader in hernia and plastic reconstructive surgery through enhanced medical education and market access strategies [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving at least 16% revenue growth for the full year 2025 compared to 2024 [16] - For 2026, the company anticipates at least 15% revenue growth from 2025, with a focus on hiring and operational efficiency [17] Other Important Information - The company announced a refinancing and upsizing of its debt facility from $40 million to $60 million, along with a $13 million equity offering, adding approximately $26 million in net cash [18] - The company has surpassed 100,000 implantations of OviTex and OviTex PRS globally, indicating strong market impact [7] Q&A Session Summary Question: Rationale for debt refinancing and equity raise - Management feels comfortable with the cash runway, stating the refinancing was proactive to avoid future amortization issues and to secure additional capital [25] Question: Guidance for 2025 and 2026 growth expectations - The company provided a conservative growth estimate for 2025, factoring in hiring and operational adjustments, with a goal of at least 15% growth for 2026 [26][27] Question: Details on Salesforce hiring - The company aims to increase its Salesforce to over 90 territory managers by Q1 2026, with a focus on hiring high-caliber talent [31][34] Question: Break-even profile - Management continues to target a break-even point in the high $20 million range per quarter, emphasizing operational efficiency [36] Question: Q4 growth expectations - The company expects at least 16% year-over-year growth in Q4, with potential upside from recent hiring and organizational improvements [46]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 increased by 26% year over year to $20.2 million, with OviTex revenue growing by 12% and OviTex PRS revenue growing by 53% [28] - Gross margin improved to 69.8% from 68.8% in the prior year, primarily due to lower charges for excess and obsolete inventory [28] - Net loss decreased to $9.9 million from $12.6 million in the prior year [30] Business Line Data and Key Metrics Changes - OviTex unit sales grew by 17% for the quarter, while PRS unit sales grew by 40% [28] - OviTex IHR revenue grew by 322% compared to 2024 and 29% sequentially over Q1 sales [9] - Liquefix revenue saw year-over-year growth of 121% this quarter [8] Market Data and Key Metrics Changes - European sales grew by 25% over Q2 last year, driven by 29% unit growth [10] - Contracts secured with three major national GPOs to improve market access for Liquefix [8] Company Strategy and Development Direction - The company aims to transition from a niche player in complex abdominal wall reconstruction to a broad portfolio provider in hernia repair [60] - A focus on building patient and outcome-centric partnerships with healthcare providers is emphasized [16] - The company is launching educational initiatives targeting teaching hospitals to engage the next generation of surgeons [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the company and the impact of recent organizational changes on sales performance [33] - The company reiterated its full-year 2025 revenue guidance, anticipating revenue in the range of $85 million to $88 million, representing growth of 23% to 27% over 2024 [30] Other Important Information - The company plans to share a patient case each quarter to highlight the real-world performance of the OviTex platform [31] - Recent publications and presentations have underscored the clinical utility of OviTex products [14] Q&A Session Summary Question: Update on Salesforce headcount and expectations for 2025 - The company has 69 territory managers and 25 account specialists, with plans to reach 76 territory managers [37][39] Question: Update on guidance and revenue cadence - The revenue cadence is expected to follow historical patterns, with a heavier second half compared to the first half [41][42] Question: Details on spending and patient-centric culture - The company is revising travel and expense policies and focusing on recruiting the right hires to enhance patient-centric culture [46][49] Question: Performance of reinforced tissue matrix contracts - Approximately 25 contracts are in place, with positive reception and a focus on patient-centric approaches to transcend existing pricing structures [51][52] Question: Confidence in reiterating sales guidance - Confidence stems from historical performance and the productivity of the sales team, with expectations for increased activity in Q4 [70][72]